# GPT-Rosalind

> OpenAI's frontier reasoning model purpose-built for life sciences — drug discovery, genomics, medicinal chemistry, and experimental design.

- Maker: OpenAI
- Line: GPT-Rosalind
- Canonical page: https://ai-tldr.dev/models/gpt-rosalind/
- Updated: 2026-09-13

## In short

GPT-Rosalind is OpenAI's first domain-specific frontier reasoning model, purpose-built for life sciences research, drug discovery, and genomics. OpenAI released it on 16 April 2026 as an API-only model. It costs $5.00 per million input tokens and $25.00 per million output tokens. You can use it through OpenAI — trusted-access program.

## Facts

| Fact | Value | Source |
| --- | --- | --- |
| Input price | $5.00 / 1M tokens (cached $0.50) | [1] |
| Output price | $25.00 / 1M tokens | [1] |
| Licence | Proprietary · API only | [2] |
| Released | 16 April 2026 | [2] |

## Sources

1. [OpenAI API changelog — gpt-rosalind-research generally available (September 8, 2026)](https://developers.openai.com/api/docs/changelog)
2. [Introducing GPT-Rosalind for life sciences research (OpenAI)](https://openai.com/index/introducing-gpt-rosalind/)

## Overview

GPT-Rosalind is OpenAI's first domain-specific frontier reasoning model, purpose-built for life sciences research, drug discovery, and genomics. Named after Rosalind Franklin, it was introduced on April 16, 2026 and is available in research preview through OpenAI's trusted-access deployment structure to qualified enterprise customers in ChatGPT, Codex, and the API. Launch partners include Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific.

The model is tuned for multi-step scientific workflows over molecules, proteins, genes, pathways, and disease-relevant biology — covering evidence synthesis, hypothesis generation, experimental planning, genomics analysis, and interpretation of research data. In OpenAI's Codex evaluations, best-of-ten GPT-Rosalind submissions ranked above the 95th percentile of human experts on a prediction task and reached the 84th percentile on a sequence-generation task.

On June 3, 2026, OpenAI shipped expanded capabilities for GPT-Rosalind, combining GPT-5.5's agentic coding and tool-use with stronger drug-discovery domains such as medicinal chemistry and genomics. The updated model uses 31% fewer tokens than GPT-5.5 while improving accuracy on quantitative-biology workloads (21.6% vs 20.4% on GeneBench).

On September 8, 2026 the model left preview: OpenAI's API changelog lists `gpt-rosalind-research` as generally available through the trusted-access program for approved internal life sciences research, with standard pricing of $5 per 1M input tokens, $0.50 per 1M cached input tokens, and $25 per 1M output tokens. Access stays gated to eligible research organizations rather than open self-serve signup.

## Benchmarks

- GeneBench (genomics & quantitative biology, accuracy): 21.6% ([source](https://openai.com/index/introducing-new-capabilities-to-gpt-rosalind/))
- Codex prediction task (best-of-ten percentile vs human experts): 95%ile ([source](https://openai.com/index/introducing-gpt-rosalind/))
- Codex sequence-generation task (percentile vs human experts): 84%ile ([source](https://openai.com/index/introducing-gpt-rosalind/))

## Pricing

- Input: $5.00 / 1M tokens
- Cached input: $0.50 / 1M tokens
- Output: $25.00 / 1M tokens

Standard pricing published with general availability on September 8, 2026; access remains gated to the trusted-access program.

Source: https://developers.openai.com/api/docs/changelog

## Strengths

- Frontier reasoning tuned for biology, drug discovery, medicinal chemistry, and genomics
- Higher accuracy than GPT-5.5 on genomics/quantitative-biology tasks while using 31% fewer tokens (per OpenAI's June 2026 update)
- Top-tier results on OpenAI's Codex prediction and sequence-generation evaluations vs human experts
- Inherits GPT-5.5's agentic coding and tool-use abilities for scientific tool integration and Codex workflows
- Trusted-access deployment structure designed for legitimate research organizations with strong governance

## Best for

- Reach for it for evidence synthesis and literature review across genomics, transcriptomics, proteomics, and clinical evidence.
- Reach for it for hypothesis generation, experimental planning, and wet-lab troubleshooting in drug-discovery workflows.
- Reach for it for medicinal-chemistry queries — turning molecules into useful drugs — and genomics or quantitative-biology analysis.
- Reach for it as an agentic lab assistant in Codex, connecting models to scientific tools and data sources via the trusted-access API.

## How to access

- [OpenAI — trusted-access program](https://developers.openai.com/api/docs/changelog) — model id `gpt-rosalind-research`

## GPT-Rosalind versions

- [GPT-6 Rosalind](https://ai-tldr.dev/models/gpt-6-rosalind/) (30 October 2026): Successor model on the GPT-6 generation, released to approved Rosalind Research organizations as `gpt-6-rosalind`.
- GPT-Rosalind (general availability) (8 September 2026): `gpt-rosalind-research` becomes generally available through the trusted-access program, with published token pricing of $5 / $0.50 cached / $25 per 1M tokens.
- GPT-Rosalind (expanded capabilities) (3 June 2026): Combines GPT-5.5 agentic coding/tool use with stronger medicinal-chemistry and genomics reasoning; 31% fewer tokens than GPT-5.5 at higher accuracy on GeneBench.
- GPT-Rosalind (initial research preview) (16 April 2026): First domain-specific frontier reasoning model from OpenAI; research preview via trusted-access in ChatGPT, Codex, and API. — this page

## FAQ

### What is GPT-Rosalind?

GPT-Rosalind is OpenAI's first domain-specific frontier reasoning model, purpose-built for life sciences research, drug discovery, genomics, and medicinal chemistry. It was introduced on April 16, 2026 and is named after Rosalind Franklin. It reached general availability on September 8, 2026 as the API model `gpt-rosalind-research`, offered to qualified research organizations through OpenAI's trusted-access program in ChatGPT, Codex, and the API.

### Who can use GPT-Rosalind?

Access is gated. OpenAI offers GPT-Rosalind to eligible enterprise customers globally through its trusted-access deployment structure, designed for organizations conducting legitimate scientific research with clear public benefit and strong governance. Launch partners include Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. Since general availability on September 8, 2026, approved organizations pay standard token pricing: $5 per 1M input tokens, $0.50 per 1M cached input tokens, and $25 per 1M output tokens.

### How does GPT-Rosalind differ from GPT-5.5?

GPT-5.5 is OpenAI's general-purpose flagship; GPT-Rosalind is a narrower model tuned specifically for life sciences workflows. The June 3, 2026 update combines GPT-5.5's agentic coding and tool use with stronger reasoning over drug-discovery domains like medicinal chemistry and genomics, using 31% fewer tokens than GPT-5.5 while improving accuracy on GeneBench (21.6% vs 20.4%).

### When was GPT-Rosalind released?

OpenAI introduced GPT-Rosalind on April 16, 2026 as a research-preview frontier reasoning model for life sciences, shipped expanded capabilities and broader scientific-workflow coverage on June 3, 2026, and moved the model to general availability as `gpt-rosalind-research` on September 8, 2026. Access stays limited to trusted-access partners throughout.

## Links

- [Introducing GPT-Rosalind for life sciences research (OpenAI)](https://openai.com/index/introducing-gpt-rosalind/)
- [OpenAI API changelog — gpt-rosalind-research generally available (September 8, 2026)](https://developers.openai.com/api/docs/changelog)
- [Introducing new capabilities to GPT-Rosalind (OpenAI, June 3, 2026)](https://openai.com/index/introducing-new-capabilities-to-gpt-rosalind/)
- [OpenAI introduces GPT-Rosalind, its drug discovery AI (pharmaphorum)](https://pharmaphorum.com/news/openai-introduces-gpt-rosalind-its-drug-discovery-ai)
- [What to know about OpenAI's life-sciences model GPT-Rosalind (Euronews)](https://www.euronews.com/health/2026/04/17/what-to-know-about-openais-new-model-for-life-sciences-research-gpt-rosalind)
- [OpenAI benchmarks (the-decoder.com)](https://the-decoder.com/openai-launches-gpt-rosalind-a-reasoning-model-built-for-life-sciences-research/)
- [OpenAI benchmarks (rdworldonline.com)](https://www.rdworldonline.com/openai-research-and-product-leads-detail-gpt-rosalind-capabilities-and-benchmarks/)

Source: AI/TLDR LLM registry, https://ai-tldr.dev/models/gpt-rosalind/